This company is no longer active
The company may no longer be operating, as it may be out of business. Find out why through their latest events.
Ekso Bionics Holdings (EKSO) Panoramica del titolo
Ekso Bionics Holdings, Inc. progetta, sviluppa, distribuisce e commercializza prodotti esoscheletrici nelle Americhe, in Europa, Medio Oriente, Africa, Asia e Pacifico e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 0/6 |
| Crescita futura | 5/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 2/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
EKSO Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Ekso Bionics Holdings, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$11.80 |
| Massimo di 52 settimane | US$13.50 |
| Minimo di 52 settimane | US$2.73 |
| Beta | 0.78 |
| Variazione di 1 mese | 25.53% |
| Variazione a 3 mesi | 30.10% |
| Variazione di 1 anno | 65.13% |
| Variazione a 3 anni | -49.89% |
| Variazione a 5 anni | -84.70% |
| Variazione dall'IPO | -99.68% |
Notizie e aggiornamenti recenti
Aggiornamento della narrazione • Apr 23
EKSO: Going Concern Warning Will Drive Bearish Outlook On Shares
Analysts have maintained their $9.50 price target for Ekso Bionics Holdings, noting that only modest adjustments were made to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any major change to the overall investment case. What's in the News Auditor WithumSmith+Brown, PC issued an unqualified opinion in the 10-K filed on February 23, 2026, while also expressing doubt about Ekso Bionics Holdings' ability to continue as a going concern, highlighting liquidity and sustainability questions for shareholders (Key Developments).Aggiornamento della narrazione • Apr 09
EKSO: Going Concern Risk And Capital Raises Will Shape Balanced Outlook
Analysts have kept their $9.50 price target for Ekso Bionics Holdings unchanged, pointing to only minor tweaks to inputs such as discount rate, revenue growth, profit margin, and future P/E assumptions as the reason for holding steady. What's in the News Filed Form 10-K for the year ended December 31, 2025, with auditor WithumSmith+Brown, PC issuing an unqualified opinion that includes doubt about Ekso Bionics Holdings continuing as a going concern (10-K filing).Aggiornamento della narrazione • Mar 25
EKSO: Reverse Merger And Going Concern Risk Will Drive Bearish Outlook
Analysts have modestly adjusted their price target for Ekso Bionics Holdings, citing small updates to inputs such as the discount rate, an assumed long term revenue growth rate of about 33.71%, and a future P/E assumption of about 43.20x. Taken together, these inputs leave their view of fair value steady at $9.50 per share.Recent updates
Aggiornamento della narrazione • Apr 23
EKSO: Going Concern Warning Will Drive Bearish Outlook On Shares
Analysts have maintained their $9.50 price target for Ekso Bionics Holdings, noting that only modest adjustments were made to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any major change to the overall investment case. What's in the News Auditor WithumSmith+Brown, PC issued an unqualified opinion in the 10-K filed on February 23, 2026, while also expressing doubt about Ekso Bionics Holdings' ability to continue as a going concern, highlighting liquidity and sustainability questions for shareholders (Key Developments).Aggiornamento della narrazione • Apr 09
EKSO: Going Concern Risk And Capital Raises Will Shape Balanced Outlook
Analysts have kept their $9.50 price target for Ekso Bionics Holdings unchanged, pointing to only minor tweaks to inputs such as discount rate, revenue growth, profit margin, and future P/E assumptions as the reason for holding steady. What's in the News Filed Form 10-K for the year ended December 31, 2025, with auditor WithumSmith+Brown, PC issuing an unqualified opinion that includes doubt about Ekso Bionics Holdings continuing as a going concern (10-K filing).Aggiornamento della narrazione • Mar 25
EKSO: Reverse Merger And Going Concern Risk Will Drive Bearish Outlook
Analysts have modestly adjusted their price target for Ekso Bionics Holdings, citing small updates to inputs such as the discount rate, an assumed long term revenue growth rate of about 33.71%, and a future P/E assumption of about 43.20x. Taken together, these inputs leave their view of fair value steady at $9.50 per share.Aggiornamento della narrazione • Mar 11
EKSO: Reverse Merger Uncertainty Will Drive Bearish Long Term Outlook
Analysts have nudged their price target on Ekso Bionics Holdings higher to $9.50 per share, reflecting updated assumptions around revenue growth, profit margin and a lower forward P/E. Together, these factors support a stronger long term valuation case at the same fair value estimate of $9.50.Aggiornamento della narrazione • Feb 24
EKSO: Reverse Merger And Revenue Slowdown Will Shape Cautious Outlook
Analysts have maintained their $9.50 price target on Ekso Bionics Holdings, citing only minor adjustments to inputs such as the discount rate, long term revenue growth assumptions, profit margin and future P/E that do not materially alter their valuation view. What’s in the News Applied Digital Cloud Corporation signed a letter of intent to acquire Ekso Bionics Holdings in a reverse merger, with Applied Digital expected to own about 97% of the combined company.Aggiornamento della narrazione • Feb 10
EKSO: Q3 Sales Recovery And Business Review Will Shape Balanced Outlook
Analysts have lifted their price target on Ekso Bionics Holdings to US$6 from US$4, citing a solid Q3 update and a company-led review of its current business as key supports for the revised valuation outlook. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher US$6 price target as a reflection of increased confidence in the company’s ability to execute on its current business plan following the Q3 update.Aggiornamento della narrazione • Jan 27
EKSO: Q3 Sales Recovery And Business Review Will Drive Future Upside
Narrative Update Analysts have lifted their price target on Ekso Bionics Holdings to $6 from $4, citing a solid Q3 report, a newly announced review of the current business, and signs that earlier order delays may have been specific to prior periods rather than ongoing. Analyst Commentary Analysts raising their price target to $6 from $4 are reacting to the recent Q3 report and the announced review of the current business, while still flagging a few key execution risks that could affect how the story plays out from here.Aggiornamento della narrazione • Jan 12
EKSO: Q3 Sales Recovery And Business Review Will Support Future Upside
Analysts have lifted their fair value estimate for Ekso Bionics Holdings from $7.75 to $9.50, citing a higher Street price target of $6.00, a solid Q3 report, and the ongoing review of the current business as key reasons for the reassessment. Analyst Commentary Recent Street research reflects a mix of optimism and caution around Ekso Bionics Holdings, with the latest price target move to US$6 framed around the recent Q3 report and the ongoing review of the current business.Aggiornamento della narrazione • Dec 26
EKSO: Q3 Sales Recovery And Business Review Will Drive Future Upside
Analysts have modestly raised their price target on Ekso Bionics Holdings to $6 from $4, citing a solid Q3 performance and signs that earlier order delays were idiosyncratic, even as they await further confirmation that the recent sales recovery is sustainable. Analyst Commentary Bullish analysts view the higher price target as a reflection of improving execution and a clearer path to value creation following the strong Q3 report and strategic review announcement.Articolo di analisi • Dec 23
Ekso Bionics Holdings, Inc.'s (NASDAQ:EKSO) Shares Bounce 29% But Its Business Still Trails The Industry
Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) shares have had a really impressive month, gaining 29% after a shaky period...
Aggiornamento della narrazione • Dec 12
EKSO: Q3 Sales Momentum Is Expected To Drive Shares Higher
Analysts have raised their price target on Ekso Bionics Holdings to $6.00 from $4.00, citing stronger than expected Q3 sales momentum, a modestly lower perceived risk profile, and improved long term growth and profitability assumptions. Analyst Commentary Bearish analysts acknowledge that the higher price target reflects a solid Q3, but emphasize that the implied upside is increasingly reliant on sustained execution against a still-early sales recovery.Aggiornamento della narrazione • Nov 27
EKSO: Sales Recovery and Increased Confidence Will Drive Future Stock Performance
Analysts have raised their price target for Ekso Bionics from $6.75 to $7.75. This change reflects stronger revenue growth expectations and a solid recent earnings report.Articolo di analisi • Aug 24
Take Care Before Jumping Onto Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Even Though It's 26% Cheaper
Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) shares have had a horrible month, losing 26% after a relatively good period...Aggiornamento della narrazione • Aug 10
Advanced Exoskeleton Devices Will Broaden Rehabilitation Market Access
The drastic reduction in Ekso Bionics Holdings' consensus price target from $34.75 to $6.75 reflects sharply lower growth and earnings expectations as seen in the substantial drop in its forward P/E multiple from 24.94x to 4.86x. What's in the News Launched eksoUniversity, an online platform offering CEU-approved courses for physical therapists and assistants in over 30 states.Articolo di analisi • Jun 22
Not Many Are Piling Into Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Stock Yet As It Plummets 31%
Unfortunately for some shareholders, the Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) share price has dived 31% in the...Articolo di analisi • Jun 22
Slammed 31% Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Screens Well Here But There Might Be A Catch
To the annoyance of some shareholders, Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) shares are down a considerable 31...
Nuova narrazione • May 01
PRIA Healthcare And National Seating Will Streamline Medicare Claims
Strategic partnerships aim to broaden distribution, streamline reimbursements, and enhance revenue growth in the personal health market.Articolo di analisi • Mar 07
It's Down 27% But Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Could Be Riskier Than It Looks
Unfortunately for some shareholders, the Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) share price has dived 27% in the...Articolo di analisi • Mar 06
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
It's been a sad week for Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ), who've watched their investment drop 17% to...Articolo di analisi • Jan 12
Even With A 39% Surge, Cautious Investors Are Not Rewarding Ekso Bionics Holdings, Inc.'s (NASDAQ:EKSO) Performance Completely
Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) shareholders are no doubt pleased to see that the share price has bounced...Articolo di analisi • Nov 12
Take Care Before Jumping Onto Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Even Though It's 27% Cheaper
Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) shareholders that were waiting for something to happen have been dealt a...Articolo di analisi • Aug 29
Investors Give Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Shares A 26% Hiding
Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) shares have had a horrible month, losing 26% after a relatively good period...Articolo di analisi • Jul 13
Many Still Looking Away From Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)
Ekso Bionics Holdings, Inc.'s ( NASDAQ:EKSO ) price-to-sales (or "P/S") ratio of 1.2x might make it look like a buy...Articolo di analisi • May 02
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00
It's shaping up to be a tough period for Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ), which a week ago released some...Articolo di analisi • Dec 20
Market Still Lacking Some Conviction On Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)
You may think that with a price-to-sales (or "P/S") ratio of 1.3x Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) is a...Articolo di analisi • Jun 19
Sentiment Still Eluding Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)
Ekso Bionics Holdings, Inc.'s ( NASDAQ:EKSO ) price-to-sales (or "P/S") ratio of 1.1x might make it look like a strong...Rendimenti per gli azionisti
| EKSO | US Medical Equipment | US Mercato | |
|---|---|---|---|
| 7D | 3.8% | -1.3% | 0.8% |
| 1Y | 65.1% | -18.6% | 20.6% |
Ritorno vs Industria: EKSO ha superato il US Medical Equipment che ha restituito -18.6 % nell'ultimo anno.
Rendimento vs Mercato: EKSO ha superato il mercato US che ha restituito 20.6 % nell'ultimo anno.
Volatilità dei prezzi
| EKSO volatility | |
|---|---|
| EKSO Average Weekly Movement | 12.3% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di EKSO è stato volatile rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale di EKSO è diminuita da 19% a 12% nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2005 | 53 | Scott Davis | www.eksobionics.com |
Ekso Bionics Holdings, Inc. progetta, sviluppa, distribuisce e commercializza prodotti esoscheletrici nelle Americhe, in Europa, Medio Oriente, Africa, Asia e Pacifico e a livello internazionale. L'azienda fornisce EksoNR, un esoscheletro robotico indossabile; Ekso Indego Therapy, un esoscheletro alimentato; Ekso Indego Personal, un'ortesi per arti inferiori alimentata; ed Ekso EVO, un esoscheletro indossabile per la parte superiore del corpo. L'azienda sviluppa anche Ekso Nomad, un'ortesi ginocchio-caviglia-piede ad alimentazione elettrica (KAFO), e il sistema di riabilitazione MediTouch BalanceTutor, un tapis roulant a perturbazione multidirezionale.
Ekso Bionics Holdings, Inc. Riepilogo dei fondamenti
| EKSO statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$42.01m |
| Utili (TTM) | -US$15.91m |
| Ricavi(TTM) | US$11.57m |
3.6x
Rapporto P/S-2.6x
Rapporto P/EEKSO è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| EKSO Conto economico (TTM) | |
|---|---|
| Ricavi | US$11.57m |
| Costo del fatturato | US$5.45m |
| Profitto lordo | US$6.11m |
| Altre spese | US$22.03m |
| Utili | -US$15.91m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -4.47 |
| Margine lordo | 52.86% |
| Margine di profitto netto | -137.61% |
| Rapporto debito/patrimonio netto | 67.0% |
Come si è comportato EKSO nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/04 16:01 |
| Prezzo dell'azione a fine giornata | 2026/05/04 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Ekso Bionics Holdings, Inc. è coperta da 7 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Gregory Chodaczek | B. Riley Securities, Inc. |
| Tom Grady | Edison Investment Research |
| Dan Scovel | Edison Investment Research |